Core Viewpoint - Under high pressure from restrictions on supply and procurement, the fundamentals of Dongya Pharmaceutical appear to be deteriorating, with a significant decline in revenue exceeding 40% in the third quarter. The company's high inventory raises concerns about potential risks in the 2025 financial report, alongside regulatory scrutiny for alleged misappropriation of raised funds [1][9]. Financial Performance - For the first three quarters, Dongya Pharmaceutical reported revenue of 596 million yuan, a year-on-year decrease of 38.08%. The net profit attributable to shareholders was -72.41 million yuan, down 260.31%, while the net profit excluding non-recurring items was -81.98 million yuan, a decline of 315.27%. In Q3 alone, revenue was 180 million yuan, down 42.67%, with a net profit of -42.18 million yuan, a drop of 432.24% [1][2]. Business Overview - Established in 1998, Dongya Pharmaceutical focuses on the research, production, and sales of chemical raw materials and intermediates, primarily in the antibacterial drug sector, including β-lactam antibiotics and quinolones. The decline in performance is attributed to reduced demand from downstream customers for β-lactam antibiotics [2][4]. Product Performance - The β-lactam antibiotics segment generated revenue of 793 million yuan, accounting for nearly 70% of the company's total revenue. The overall market for systemic antibacterial drugs has faced significant fluctuations due to ongoing policy pressures, with a reported 12.68% decline in sales in 2024 [4][5]. Inventory Concerns - As of now, the company holds nearly 700 million yuan in inventory. The substantial inventory raises questions about potential impairment risks, especially given the ongoing decline in the company's core business [7][9]. Regulatory Issues - Dongya Pharmaceutical has received a regulatory notice for allegedly misappropriating raised funds, with discrepancies found between the actual use of funds and the disclosures made in the IPO prospectus. This violation of disclosure regulations has led to corrective measures mandated by the regulatory authority [9][10]. Project Delays - The company has announced delays in two key projects funded by convertible bonds, pushing the expected production start date to December 2025. This decision is influenced by various factors, including industry policy changes and increased market competition [10].

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. has received a corrective order from the Zhejiang Securities Regulatory Bureau, requiring the company to rectify issues related to the use of raised funds and information disclosure [8][10]. Financial Data - The third-quarter financial report for 2025 has not been audited [3]. - The company reported that the net amount raised from its initial public offering (IPO) was approximately RMB 782.44 million after deducting various fees [37]. Rectification Measures - The company plans to permanently adjust the use of funds from the R&D center construction project to an administrative complex, while maintaining the existing R&D areas [11][44]. - The company has organized training for relevant personnel to enhance compliance awareness and prevent future issues related to fund management [13][14]. Board and Supervisory Meetings - The 11th meeting of the 4th Board of Directors and the 10th meeting of the 4th Supervisory Board were held on October 30, 2025, to discuss and approve the third-quarter report and the adjustment of the R&D center project [19][29]. - Both meetings confirmed that the adjustments to the project would not negatively impact the company's economic benefits or the implementation of the IPO fundraising projects [33][45]. Compliance and Governance - The company emphasizes the importance of improving internal controls and compliance with securities laws following the corrective order [15]. - The company aims to enhance its governance and operational standards to protect the interests of shareholders and investors [15].

Core Viewpoint - East Asia Pharmaceutical (605177.SH) reported a significant decline in revenue and incurred losses in the first three quarters of 2025 [1] Financial Performance - The company achieved a revenue of 596 million yuan in the first three quarters, representing a year-on-year decrease of 38.08% [1] - The net profit attributable to the parent company was a loss of 72.41 million yuan [1] - The non-recurring net profit also showed a loss of 81.98 million yuan [1] - Basic earnings per share were reported at -0.63 yuan [1]

10月30日，东亚药业发布2025年三季报。报告显示，公司前三季度营业收入为5.96亿元，同比下降 38.08%；归母净利润为-7240.96万元，同比下降260.31%；扣非归母净利润为-8198.47万元，同比下降 315.27%；基本每股收益-0.63元。 报告期内，东亚药业基本每股收益为-0.63元，加权平均净资产收益率为-3.93%。 以10月30日收盘价计算，东亚药业目前市盈率（TTM）约为-14.20倍，市净率（LF）约为1.25倍，市销 率（TTM）约为2.40倍。 2025年前三季度，公司毛利率为25.96%，同比下降1.02个百分点；净利率为-12.15%，较上年同期下降 16.84个百分点。从单季度指标来看，2025年第三季度公司毛利率为16.29%，同比下降13.08个百分点， 环比下降9.43个百分点；净利率为-23.37%，较上年同期下降27.40个百分点，较上一季度下降13.00个百 分点。 资料显示，浙江东亚药业股份有限公司位于浙江省台州市临海市台州湾经济技术开发区东海第五大道21 号，成立日期1998年2月6日，上市日期2020年11月25日，公司主营业务涉及化学原料药、医药 ...

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. has released a rectification report addressing issues related to the use of raised funds, as highlighted by the Zhejiang Securities Regulatory Bureau [1][2][3] Group 1: Rectification Measures - The company plans to adjust the use of raised funds, improve review procedures, and enhance information disclosure to strengthen internal control governance [1][2] - The adjustment includes converting the construction project of the R&D center into a comprehensive administrative building, while maintaining the existing R&D area [2] - The company has organized specialized training for its board members and management to enhance compliance awareness and information disclosure management [2] Group 2: Compliance and Governance - The rectification aims to improve the company's internal control governance, ensuring compliance and promoting sustainable development [3] - The announcement did not indicate any significant impact on the company's daily operations due to these issues [3]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于浙江证监局对公司采取责令改正措施决定的 整改报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"）于近日收到中国证券监督 管理委员会浙江监管局（以下简称"浙江证监局"）出具的《关于对浙江东亚药 业股份有限公司采取责令改正措施的决定》（【2025】224 号）（以下简称"决 定书"），要求公司就《决定书》中所提出的问题进行整改。具体内容详见公司 于 2025 年 10 月 23 日在上海证券交易所网站（www.sse.com.cn）披露的《关于 公司收到浙江证监局行政监管措施决定书的公告》（公告编号：2025-048）。 公司收到浙江证监局发来的《决定书》后高度重视并立即向公司全体董事、 监事、高级管理人员及相关部门负责人进行了通报和传达，对《决定书》中涉及 的事项 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于调整首次公开发行股票募投项目中的 研发中心建设项目用途的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 为提高浙江东亚药业股份有限公司（以下简称"公司"）资产的使用效 率，公司拟将首次公开发行股票募投项目中的研发中心建设项目（以下简称"研 发中心建设项目"）所投建的研发楼永久调整为研发行政综合楼，现有供研发使 用的区域保持不变，同步调整部分建筑面积供其他行政部门综合使用，并将根据 公司研发项目实际情况，适时增加研发实验区域和相关研发设备。 ● 本次调整事项已经公司第四届董事会第十一次会议、第四届监事会第十 次会议分别审议通过，监事会已就此事项发表同意意见。本次调整研发中心建设 项目用途的事项尚需提交公司股东大会审议。 ● 本次对首次公开发行股票募投项目调整的事项能提高公司资产整体使用 效 ...

本次会议由监事会主席徐菁女士主持。会议的召集、召开符合《中华人民共和国 公司法》等法律、法规和《公司章程》的有关规定。出席会议的监事对各项议案进行 了认真审议并做出了如下决议： 二、监事会会议审议情况 （一）审议通过《关于 2025 年第三季度报告的议案》 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届监事会第十次会议于 2025 年 10 月 30 日（星期四）在浙江省台州市临海市台州湾经济技术开发区东海第五大道 21 号二楼会议室五以现场表决的方式召开。会议通知已于 2025 年 10 月 24 日以电子邮 件的方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人。 表决情况：同意 3 票，反对 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 本议案已经公司董事会审计委员会审议通过，并同意提交董事会审议。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《2025 年第三季度报告》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届董事会第十一次会议于 2025 年 10 月 30 日（星期四）在浙江省台州市临海市台州湾经济技术开发区东海第 五大道 21 号二楼会议室五以现场结合通讯的方式召开。本次会议通知于 2025 年 10 月 24 日以电子邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由公司董事长池骋先生主持，监事、高管列席会议。本次会议的召集、召 开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 经各 ...

格隆汇10月30日丨东亚药业(605177.SH)发布三季报，2025年前三季度实现营业总收入5.96亿元，同比下 降38.08%；归属母公司股东净利润-7240.96万元，上年同期净利润为4516.92万元；基本每股收益为-0.63 元。 ...